- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr Herbst on the Evolution of Targeted Therapies for EGFR+ NSCLC
August 2nd 2024, 1:20pm
Bridging the Gaps in Lung Cancer
Roy S. Herbst, MD, PhD, discusses the evolution of targeted therapies in EGFR-mutated NSCLC, as well as hurdles associated with biomarker testing.
Dr Rotow on Challenges With Targeting CNS Metastases in Lung Cancer
August 1st 2024, 2:00pm
Bridging the Gaps in Lung Cancer
Julia Rotow, MD, discusses existing unmet needs for patients with lung cancer and CNS metastases.
Dr Backhus on Defining Borderline-Resectable Lung Cancer
August 1st 2024, 1:00pm
Bridging the Gaps in Lung Cancer
Leah Backhus, MD, MPH, FACS, discusses the evolving definition of borderline resectable lung cancer.
Two Leading Experts Detail Hot Topics in GI Cancers to Be Presented at Upcoming ISGIO Meeting
July 31st 2024, 12:00pm
Eileen M. O’Reilly, MD, and Tanios S. Bekaii-Saab, MD, FACP, discuss key topics in gastrointestinal cancer to be presented during the 2024 ISGIO Meeting.
Liquid Biopsy in Oncology: Have We Just Scratched the Surface?
July 30th 2024, 2:00pm
Circulating tumor cells and circulating extracellular vesicles should be integrated into liquid biopsy assays to improve their utility in oncology.
Experts Delve into Case-Based Discussions of Locally Advanced Lung Cancer Management
July 29th 2024, 2:10pm
International Lung Cancer Congress
A panel of oncologists engage in a case-based discussion of patients with locally advanced disease at the 25th Annual International Lung Cancer Congress.
ctDNA Carves a Precise Path for Early-Stage NSCLC Management
July 29th 2024, 12:00pm
David R. Gandara, MD, discusses research reflecting the capabilities of ctDNA assays to detect MRD and prognosticate adjuvant NSCLC treatment outcomes.
Experts Weigh in on Topic of Frontline Osimertinib Alone or With Chemo in EGFR-Mutant NSCLC
July 26th 2024, 3:00pm
International Lung Cancer Congress
Jonathan W. Riess, MD, MS, and James Chih-Hsin Yang MD, PhD, debate the benefits of upfront osimertinib with/without chemotherapy in EGFR-mutant NSCLC.
Dr Sands on the Evolving Role of ADCs in SCLC Management
July 25th 2024, 11:55pm
Bridging the Gaps in Lung Cancer
Jacob Sands, MD, discusses updates to the role of antibody-drug conjugates in the treatment of patients with small cell lung cancer.
Dr Hirsch on the Treatment of NRG1 Fusion+ NSCLC
July 25th 2024, 11:45pm
Bridging the Gaps in Lung Cancer
Fred R. Hirsch, MD, PhD, discusses the activity of HER3-directed agents in patients with non–small cell lung cancer harboring NRG1 mutations.
MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer
July 25th 2024, 12:00pm
International Congress on the Future of Breast Cancer East
Lajos Pusztai, MD, DPhil, discusses molecular residual disease monitoring in early-stage breast cancer.
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
July 25th 2024, 12:15am
Bridging the Gaps in Lung Cancer
Julia Rotow, MD, discusses the importance of comprehensive biomarker testing for all patients with NSCLC.
Dr Sabari on Barriers to Biomarker Testing in NSCLC
July 25th 2024, 12:15am
Bridging the Gaps in Lung Cancer
Joshua K. Sabari, MD, discusses barriers to biomarker testing in patients with non–small cell lung cancer.
Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC
July 24th 2024, 1:25am
Leah Backhus, MD, MPH, FACS, discusses the evolving definition of surgical resectability in patients with borderline resectable NSCLC.
Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC
July 24th 2024, 1:20am
Bridging the Gaps in Lung Cancer
Roy S. Herbst, MD, PhD, discusses the importance of consulting a multidisciplinary tumor board when making treatment decisions for patients with NSCLC.
Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer
July 22nd 2024, 10:00pm
International Congress on the Future of Breast Cancer East
Sonya Reid, MD, MPH, discusses barriers to universal germline testing utilization in breast cancer, particularly among underserved populations.
Research Propels Additional Options into the Advanced HER2+ Breast Cancer Armamentarium
July 22nd 2024, 9:39pm
International Congress on the Future of Breast Cancer East
Sarah Sammons, MD, discusses the evolving treatment landscape for metastatic HER2-postive breast cancer.
Research With ctDNA Continues to Pave the Way Toward Optimal Breast Cancer Management
July 22nd 2024, 9:27pm
International Congress on the Future of Breast Cancer East
Circulating tumor DNA is in constant flux, rendering its evaluation potentially useful in metastatic breast cancer management.
De-Escalation Strategies, Biomarkers Could Refine Treatment Algorithm for Early-Stage HER2+ Breast Cancer
July 20th 2024, 8:20pm
International Congress on the Future of Breast Cancer East
Sara M. Tolaney, MD, MPH, discusses the use of HER2-directed therapy in the curative setting for HER2-positive breast cancer.
Dr Feldman on New Approaches for Decreasing the Risk of Breast Cancer–Related Lymphedema
July 20th 2024, 7:50pm
International Congress on the Future of Breast Cancer East
Sheldon Feldman, MD discusses new approaches for decreasing the risk of and managing breast cancer¬–related lymphedema.